James Dean’s unflinching portrayal of adolescent disillusionment resonated with young audiences who found their struggles reflected on screen with unprecedented authenticity.

It was hard to pigeonhole him: in 2014, he starred in the dystopian western The Rover; in 2015, he played photographer Dennis Stock – not James Dean – in the biopic Life; and in 2017, he was ...

You will find the small town of Fairmount tucked away in the heart of Indiana. Fairmount, Indiana, comes alive with the celebration of its most famous resident, James Dean. That's right. This ...

How did James Dean die? During the early evening of September 30, 1955, Dean was behind the wheel of his brand-new $7,000 Porsche Spyder convertible, en route to a car race in Salinas, California ...

Former Superman star Dean Cain has come out strongly against filmmaker James Gunn for his recent remarks about the superhero. The actor, known for portraying th ...

Raymond James cited the defensive nature of Crombie’s long-term duration and high credit-quality cash flows as key factors supporting the Strong Buy rating, noting the REIT is attractively ...

Wells Fargo & Company (NYSE:WFC) is one of the Best Large Cap Value Stocks to Invest In. Raymond James downgraded the company’s stock from “Outperform” to “Market Perform,” noting the ...

Raymond James noted that CACI’s national security focus, which comprises about 94% of its sales, combined with strong execution, has pushed the stock to the firm’s previous price target.

The price target increase represents a 21.75x price-to-earnings multiple applied to Raymond James’ 2026 earnings estimate for the company, up from the previous 21.0x multiple.

Stock Yards Bancorp received the Raymond James Community Bankers Cup for exceptional performance among community banks in 2024.

Investing.com - Raymond James initiated coverage on Janux Therapeutics (NASDAQ: JANX) with an Outperform rating and a $65.00 price target. The stock, currently trading at $25.61, has seen ...

Raymond James Financial reported adjusted quarterly earnings per share of $2.42 for the period ending March 31, missing analyst estimates of $2.45.